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Abstract
Background: To prepare field sites for malaria vaccine trials, it is important to determine baseline antibody and T
cell responses to candidate malaria vaccine antigens. Assessing T cell responses is especially challenging, given
genetic restriction, low responses observed in endemic areas, their variability over time, potential suppression by
parasitaemia and the intrinsic variability of the assays.
Methods: In Part A of this study, antibody titres were measured in adults from urban and rural communities in
Ghana to recombinant Plasmodium falciparum CSP, SSP2/TRAP, LSA1, EXP1, MSP1, MSP3 and EBA175 by ELISA, and
to sporozoites and infected erythrocytes by IFA. Positive ELISA responses were determined using two methods. T
cell responses to defined CD8 or CD4 T cell epitopes from CSP, SSP2/TRAP, LSA1 and EXP1 were measured by ex
vivo IFN-g ELISpot assays using HLA-matched Class I- and DR-restricted synthetic peptides. In Part B, the
reproducibility of the ELISpot assay to CSP and AMA1 was measured by repeating assays of individual samples
using peptide pools and low, medium or high stringency criteria for defining positive responses, and by comparing
samples collected two weeks apart.
Results: In Part A, positive antibody responses varied widely from 17%-100%, according to the antigen and
statistical method, with blood stage antigens showing more frequent and higher magnitude responses. ELISA titres
were higher in rural subjects, while IFA titres and the frequencies and magnitudes of ex vivo ELISpot activities were
similar in both communities. DR-restricted peptides showed stronger responses than Class I-restricted peptides. In
Part B, the most stringent statistical criteria gave the fewest, and the least stringent the most positive responses,
with reproducibility slightly higher using the least stringent method when assays were repeated. Results varied
significantly between the two-week time-points for many participants.
Conclusions: All participants were positive for at least one malaria protein by ELISA, with results dependent on the
criteria for positivity. Likewise, ELISpot responses varied among participants, but were relatively reproducible by the
three methods tested, especially the least stringent, when assays were repeated. However, results often differed
between samples taken two weeks apart, indicating significant biological variability over short intervals.
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Naturally-acquired immune responses to Plasmodium
spp. infection target a variety of pre-erythrocytic and
blood stage antigens of the parasite[1]. When an ende-
mic population demonstrates a degree of clinical or
parasitological resistance, identifying an association
between immunological recognition of a given antigen
and resistance to malaria may indicate the antigen’s
potential value as a malaria vaccine candidate. Defining
background responses is also useful for planning vaccine
trials in endemic areas, due to the need to distinguish
vaccine-induced responses from the baseline of naturally
acquired responses once the vaccine is administered.
Additionally, knowing this baseline and comparing
immune responses post immunization with the
responses obtained in malaria-naïves helps to assess
whether naturally-acquired responses can be boosted by
the candidate malaria vaccine.
Many studies have used immunofluorescence antibody
assays (IFA) and enzyme linked immunosorbent assays
(ELISA) to measure naturally acquired anti-malaria anti-
bodies. In some cases, immunological studies have
demonstrated an association between positive anti-mer-
ozoite[2] or anti-pre-erythrocytic[3] antibodies and inci-
dence of malaria infection. IFA positivity has generally
been defined by titres equal to or higher than the dilu-
tion of control sera not giving a positive immunofluor-
escence with the test antigen[4,5], while ELISA positivity
has generally been defined as titres greater than the
mean + 3 SD of the negative control samples ("classical
approach”). It has been pointed out that there are pro-
blems associated with the classical approach when nega-
tive and positive samples are not well separated and the
background levels of controls are variable; in this case, a
latent class model may better estimate the proportion of
positive samples [6]. However, it seems best suited to
estimating the proportion of positive samples rather
than identifying each sample as positive or negative,
w h i c hi st h eo b j e c t i v eo ft h i ss t u d y ,a n ds ow a sn o t
used. Because the “the classical method” yielded many
positive samples due to the small SD of negative con-
trols, a second, more stringent method was also applied,
in which a sample was deemed positive if it met criteria
for the first method and simultaneously showed an opti-
cal density (OD) ≥ 0.5 at a dilution of >1/100.
Defining baseline, naturally acquired T cell immunity
is more challenging, since activities of T cells measured
using different assays in malaria endemic areas are low,
vary over time[7-9] and are HLA-restricted[9]. Earlier
studies, using proliferative or cytotoxic T cell responses
to measure T-cell immunity, identified various epitopes
within CSP [10-13], MSP1 [14-19], LSA1 SSP2/TRAP
CSP [20-22] and AMA1[23,24] that induced recall
responses in residents of endemic areas. In general,
these T cell responses were short lived and did not
clearly correlate with natural-transmission induced
immunity defined as resistance to clinical malaria.
Moreover, patent infections with P. falciparum appeared
to suppress T cell responses[25]. Subsequently, ex vivo
ELISpot assays were shown to be more sensitive than
CTL assays [26,27]. However, ELISpot responses were
also of low magnitude [9] and relatively unstable over
time [7-9]. In studies in The Gambia and Kenya [28],
positive ELISpot activities ranged from 28-34 sfc/m to
SSP2/TRAP, 32-60% of volunteers responded, and
responses differed when measured one year apart [9].
With MSP-1, responses differed when measured three
weeks apart[8]. Such studies relied on a single assay per
sample, albeit often using replicate wells; so far there
have been no studies reporting whether such single
assays reproducibly represent T cell immunity and thus
whether differences measured at different time points
might reflect intrinsic variation in the assay as much as
changing T cell function.
ELISpot assays are generally defined as positive when
a statistically significant difference is found between test
samples and medium controls using the Student t test
[29-31] or chi-square comparison[32], but often mean
sfc/m induced by an antigen have been low and within
the range of medium-only controls[29,33].
To assess baseline immune responses as well as their
reproducibility, in preparation for vaccine trials in ende-
mic areas of West Africa, healthy adult subjects were
recruited from two sites in southern Ghana, the rural
community of Mampong about 35 kilometres northeast
of Accra, and the urban community of Legon, a north-
ern suburb of Accra and site of the University of Ghana.
In Part A of this study, IFA was used to measure antibo-
dies to sporozoites and blood stage parasites, and ELISA
was used to measure antibodies to the candidate recom-
binant protein vaccine antigens CSP, SSP2/TRAP, EXP1,
LSA1, MSP1 and MSP3[10-24,34]. Antibody assays were
defined as positive using the two approaches described
above. Ex vivo interferon-g (IFN-g) ELISpot assays were
also performed, using fresh PBMC stimulated with
HLA-matched peptides from the candidate antigens
CSP, SSP2/TRAP, EXP1, LSA1 and LSA3. In the ELI-
Spot assays, positive activity was determined by requir-
ing a statistically significant difference between test
sample (done in quadruplicates) and medium control
using Student’s t test, plus a 2-fold greater value than
medium controls and at least a 10 sfc/m difference
between test sample and medium controls.
Part B of the study was conducted two and a half
years later using a different set of 12 volunteers, to
assess the intrinsic reproducibility of the ELISpot assay.
Cell samples were drawn from each study volunteer
approximately two weeks apart and each sample was
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assay variability. Reproducibility of the assay was defined
as the proportion of assays yielding either all positive or
all negative results in the three replicate assays from a
single sample time point while reproducibility over time
was defined by comparing results from two time points.
Peptide pools spanning the full length of the test anti-
gens CSP and AMA1 were used for stimulation in Part
B rather than HLA-matched peptides, as a more
straightforward approach that avoided having to perform
HLA typing for each volunteer. Three statistical meth-
ods using different cut-off criteria of varying stringency
were used to define positive responses to see which pro-
vided optimal results; (1) Least stringent: a greater than
20 sfc/m difference between peptide stimulated samples
and medium controls; (2) Medium stringent (same as
Part A): a significant difference on Student’s t test com-
paring test samples and medium controls, at least two-
fold difference comparing test samples and medium
controls, and at least a 10 sfc/m difference between test
samples and medium controls; and (3) Most stringent:
based on criteria established for chronically HIV-
infected subjects where a positive response was defined
as a minimum of 55 sfc/m and a 4-fold difference over
the medium controls [35]. Volunteers who developed
positive ELISpot activities to one or more peptide pools
were designated as positive responders.
Methods
Ethics
This study was conducted according to a human use
protocol “Quality Control of Immunological Reagents
and Validation of Improvements to Immunological
Assays in Support of Malaria Vaccine Trials,” approved
by Institutional Review Boards at the Noguchi Memorial
Institute for Medical Research (NMIMR) and the Naval
Medical Research Center (NMRC). NMIMR holds a
United States Government Federal Wide Assurance
(FWA00001824) from the Office for Human Research
Protections, as does NMRC (FWA00000152). NMRC
also holds a Department of the Navy Addendum to the
FWA for human subject protections. The protocol was
conducted in accordance with all federal regulations
regarding the protection of human participants in
research including The Nuremberg Code, The Belmont
Report, The Helsinki Declaration (1964 and as subse-
quently amended), 32 CFR 219 (The Common Rule)
and all regulations pertinent to the Department of
Defense, the Department of the Navy, the Bureau of
Medicine and Surgery of the United States Navy and
internal NMRC policies for human subject protections
and responsible conduct of research. All NMRC and
NMIMR personnel contributing to or performing
human research efforts were certified as having
completed human research ethics education curricula
and training under the direction of the NMRC Office of
Research Administration (ORA) and Human Subjects
Protections Program (HSPP).
Study site
Mampong town with a total population of approxi-
mately 8000 is located in the Akuapem North district in
the Eastern Region of Ghana about 35 km northeast of
Accra. It lies on the Akuapem-Togo mountains range,
with an elevation ranging between 381 m and 487.7 m
a b o v es e al e v e l .T h es p o k e nl a n g u a g ei nM a m p o n gi s
Twi and the major occupation is farming, although a
substantial proportion of individuals work in the district
offices, hospital or schools. Health services are provided
by the Ghana Health Service through the District Health
Management Team, the Tetteh Quarshie Memorial
Hospital, the Centre for Scientific Research into Plant
Medicine, and also by some private clinics and tradi-
tional healers. The climate is cooler than in Accra and
the area receives on average about 2000 mm of rainfall
a year. Malaria transmission occurs throughout the year,
but most malaria admissions at the district hospital
occur during the months of April to November. Among
21 residents of Mampong sampled for a baseline study
of immune responses in September 2002, a third (7/21)
had peripheral P. falciparum parasitemia detected by
thick film examination. Malaria is the leading cause of
pediatric admissions and outpatient attendance at the
district hospital.
The Legon area is approximately 10 km north from the
centre of the capital city, Accra. It is well settled and home
to the University of Ghana that has a large student popula-
tion of over 20,000. Accra and its environs lie on a rela-
tively flat coastal plain with the highest elevation being
less than 100 m above sea level. Rainfall is less intense and
less frequent than in Mampong. The average annual rain-
fall is below 1000 mm with more than half falling between
April and June. Malaria transmission follows the pattern
of rainfall and most malaria admissions to the health facil-
ities occur between May and August. Malaria transmission
in this urbanized and settled area occurs mainly along the
peri-urban fringes that have suitable breeding sites for the
anopheles vector in uncompleted buildings and excavated
areas. In a survey of 20 individuals for a baseline study of
immune responses, none were positive by thick blood film
examination, and in a recent (May 2010) screen of 111
volunteers for another study only one was positive by
thick film examination.
The study is based on the rationale that transmission
and therefore immunity differs between Mampong and
Legon. Part A of this study was conducted on blood
samples drawn in April 2005 and Part B on samples
drawn in October 2007.
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Eligibility criteria for the study were the following: age
18-55 years; males or females who were not pregnant or
nursing; normal screening medical history and physical
examination; hemoglobin > 1 0g / d L ;a b s e n c eo fk n o w n
immunodeficiency (> 400 CD4 + T cells/μL); and nega-
tive hepatitis B and C serology.
Sample collection
Blood was obtained by venipuncture and transferred
into heparinized flasks using aseptic techniques. All
blood samples were transported in cool boxes to the
Department of Immunology of the NMIMR for analy-
sis. Peripheral blood mononuclear cells (PBMCs) were
separated from the blood samples by density centrifu-
gation, washed and counted. Plasma obtained from the
same separation procedure was distributed into ali-
quots and stored at -80°C for assessment of antibody
levels. Blood smears were stained with Giemsa and
examined for the presence of Plasmodium species
using light microscopy.
Control blood samples
Sera from malaria-naïve adults from Denmark and the
USA were also used in ELISA and IFA assays.
HLA typing
For each participant in Part A, low-moderate resolution
HLA typing for HLA-A, HLA-B, and HLA-DR was con-
ducted using the ABDR SSP Unitray system (Pel-Freez,
Brown Deer, WI) according to the manufacturer’s
instructions.
Synthetic peptides and peptide pools
For Part A, thirty-two short peptides (8-11 amino acids)
with known restriction by HLA-A or HLA-B alleles and
25 long peptides (15-34 amino acids) that were DR epi-
topes from CSP, SSP2/TRAP, EXP1, LSA1 and LSA3
[36,37] were synthesized commercially (Chiron Technol-
ogies, Clayton, Victoria, Australia) and were used to
assess IFN-g ELISpot responses. Positive control pep-
tides for CD8 + T cell-mediated responses consisted of
HLA-A2.1 or -A3 restricted peptides derived from CMV
or influenza virus. Purified protein derivative (PPD) (Sta-
tens Serum Institute, Copenhagen) was used as a posi-
tive control for CD4+ T cell responses.
For Part B, ELISpot assays used peptide pools of 15
amino acid (aa) synthetic peptides overlapping by 11
aa (Chiron Technologies, Clayton, Victoria, Australia)
covering full length CSP and AMA1(>80% purity).
T h e s ew e r ec o m b i n e di n t on i n ep o o l sf o rC S P( C p 1 -
Cp9) containing 3-12 peptides per pool and 12 pools
for AMA1 (Ap1-Ap12) containing 10-12 peptides per
pool [31].
Enzyme-linked immunosorbent assay (ELISA)
The P. falciparum recombinant proteins used in the
ELISA assays; CSP, SSP2/TRAP, LSA1, EXP1, MSP1,
MSP3, EBA175 have been previously described [38-43].
Stock solutions of P. falciparum recombinant proteins
were diluted in phosphate buffered saline, pH 7.2, to the
optimal concentration of each antigen (0.1-4 μg/ml).
ELISA was performed as previously described[44] using
quadruplicates of serum diluted two-fold from 1/50 to
1/5120. The endpoint titre of antibodies was defined as
the calculated serum dilution yielding an optical density
of 0.5 in the assay.
Analysis of positive end points
To determine whether the ELISA activity was defined as
positive, two methods were used. The first was an OD
that was above the mean of control negative donors
(Danish volunteers with no previous exposure to
malaria) + 3 standard deviations (SD). Since these differ-
ences were often small, a second quantitative method
was applied: a positive activity was defined as an OD ≥
0.5 at a dilution of >1/100 and greater activity than con-
trol sera + 3 SD. The numbers of total positive ELISA
activities per volunteer was determined in urban and
rural volunteers using both methods.
Immunofluorescent Antibody Assay (IFA)
P. falciparum (strain 3D7) sporozoite-specific antibodies
were assayed by immunofluorescent staining of air-dried
P. falciparum sporozoites, and P. falciparum (strain
3D7)-infected erythrocytes cultured in vitro, as described
previously[45].
Ex vivo IFN-g ELISpot Assays
Part A
ELISpot assays were performed as previously described
(42) using freshly isolated PBMC in quadruplicate using
400,000 cells/well. Each volunteer’sP B M Cw e r et e s t e d
against 8-11-mer HLA Class I binding peptides, or long
15-34-mer HLA Class II binding peptides that matched
the volunteer’sH L At y p e( 1 0μg/mL). To reduce the
number of ELISpot assays some peptides were combined
into mixtures: long peptides: CSP D44 + D49, D46 +
D47; SSP2/TRAP, D51-D59; LSA1 D64-D68; LSA3, D70
+ D72; EXP1 D60 + D61 (6 peptide mixtures + 3 single
peptides = 9 stimulants); short peptides: CSP D2 + D3,
D4 + D5, SSP2/TRAP D12-D14, LSA1 D23-D26, LSA3
D31-35, EXP1 D18-D21. (6 peptide mixtures + 12 single
peptides = 18 stimulants). PPD was used as a positive
control for PBMC biomarkers[46], and the negative con-
t r o lw a sm e d i u mo n l ya su s e db yo t h e r s( f o re x a m p l e
[47]). CEF peptides (which include epitopes from cyto-
megalovirus, Epstein-Barr virus and influenza virus
recognized by CD8+ T cells) were included in assays as
positive controls.
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To identify positive ELISpot activities, differences
between means of peptide-stimulated and non-stimu-
lated (medium only controls) were compared as used in
current NMRC vaccine trials based on previously
described methods[48]. The assay was considered posi-
tive if there was (1) a statistically significant difference
between the number of spot forming cells in triplicate
or quadruplicate test wells and triplicate or quadrupli-
cate control wells (Student’s two tailed t-test), plus (2)
at least a doubling of spot forming cells in test wells
relative to control wells, and (3) a difference of at least
10 spots between test and control wells (modified from
≥ five spots as previously described[48]. The average of
medium controls was subtracted from test samples and
reported as adjusted sfc/m PBMC. Any well that con-
tributed more than 50% of the standard deviation of the
quadruplicate and which was either three-fold greater or
lower than the mean of the remaining cells were dis-
carded as an outlier. The volunteer was designated as a
responder at a single time point if his/her PBMC tested
positive against at least one of the peptides for a given
antigen.
Part B
ELISpot assays used pools (at 10 μg/mL) of synthetic
15-mer peptides spanning full length CSP or AMA-1
based on the premise that at least one peptide within a
pool should have the correct sequence recognized by
any HLA within the study population. Twelve volunteers
were each sampled up to four times; samples for CSP
were drawn on day 0 and day 14, and samples for
AMA1 were drawn on day 9 and day 21. Thus the two
sample time-points selected to control short term repro-
ducibility were approximately two weeks apart for each
antigen. Frozen PBMC aliquots from each sample were
then tested in three separate ELISpot assays (1, 2 and 3)
each performed on different days, and each sample from
each assay was performed in triplicate. Each sample was
tested with either 9 CSP peptides/peptide pools (Cp1 -
Cp9) or 12 AMA1 peptides/peptide pools (Ap1 - Ap12)
at 10 μg/mL. Positive controls were ConA (mitogen for
cell viability) and CEF (a pool of peptides from cytome-
galovirus, Epstein Barr virus and influenza virus that
specifically stimulate CD8+ T cells).
Statistical analysis
To distinguish specific ELISpot responses, ELISpot
activities using CSP or AMA1 peptide pools were com-
pared with medium only controls and specific activity
was determined using three methods of increasing strin-
gency. Method 1: average of peptide pool stimulated
activity minus that of the average of medium controls,
with an arbitrary cut off of 20 sfc/m. Method 2: that
used in Part A. Method 3: the cut off described for HIV
gag protein[8], namely a median of >55 sfc/m and at
least four-fold greater than the median of medium-only
controls. As in Part A, a volunteer was designated as a
responder at a given time point if his/her PBMC tested
positive against at least one of the peptide pools for a
given antigen.
Results
Participant flow
In Part A, 35 healthy adult volunteers recruited in
Legon (n = 14) and in Mampong (n = 21) met the elig-
ibility criteria and passed clinical and laboratory screen-
ing and were HLA-typed. Sera were tested in IFA and
ELISA. PBMC were collected from 30 of these volun-
teers (Legon n = 13, Mampong n = 17) and fresh
PBMC were stimulated with Class I and Class II pep-
tides in ELISpot assays. Volunteer identification num-
bers, parasitaemia status and the tests performed are
shown in Additional File 1 for the two communities.
In Part B, 12 new urban volunteers donated PBMC on
four different days. The PBMC were frozen and tested
in ELISpot assays using pools of overlapping peptides
spanning the length of CSP and AMA1. Of these 12,
seven were included in the analysis of reproducibility.
Five were excluded because sampling was incomplete or
else there were insufficient PBMCs to complete the ana-
lysis. Two of the seven volunteers (v1001 and v1041)
had blood drawn only on two of the four sample days
but were included for the antigen for which the sample
set was complete.
Antibody responses
IFA titres of urban and rural volunteers
The geometric mean anti-sporozoite IFA titres were 860
and 580 for residents of Accra and Mampong, respec-
tively (Figure 1). The difference in titres between the
two sites was not significant (P = 0.44, two tailed t-test
on log transformed data). Geometric mean anti-infected
erythrocyte titres were 22,000 and 55,000 in samples
from Accra and Mampong, respectively, which likewise
were not significantly different although there was a
trend toward higher responses in the rural community
(P = 0.081, two tailed t-test, log transformed). Sera from
malaria-naive North American subjects did not react in
IFA at dilutions greater than 1:10 (sporozoites) or 1:20
(infected erythrocytes).
ELISA titres of urban and rural volunteers
Activity was defined as the calculated serum dilution
yielding an optical density of 0.5 in the assay[49]. The
ELISA titres of 14 urban and 21 rural volunteers to
seven P. falciparum candidate vaccine antigens are
shown in Figure 2. While there are limitations to com-
paring titres to different antigens measured in different
ELISA assays, group mean titres against the sporozoite
antigens CSP and SSP2/TRAP were approximately ten-
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gens MSP1, MSP3, and EBA175, consistent with the
lower IFA titres against sporozoites compared to
infected erythrocytes. There was a trend for higher titres
against all antigens in the Mampong subjects compared
with those from Legon, although the difference was sta-
tistically significant only with MSP3.
The several antibody responses measured in each indi-
vidual were moderately well correlated. In pair-wise cor-
relations, log transformed ELISA titres to each of the
four primarily erythrocytic stage antigens (MSP1, MSP3,
EBA175, EXP-1) were correlated with each of the others
(R = 0.5-0.7, p = 0.003-0.0001) and to the IFA titres
against infected erythrocytes (R = 0.4-0.6, p = 0.03-
0.0001). Similarly, ELISA titres against the three pre-ery-
throcytic stage antigens (CSP, SSP2/TRAP, LSA1) were
significantly correlated with each other and with the
sporozoite IFA titres (R = 0.5-0.6, p = 0.007-0.0005),
except that titres against SSP2/TRAP were not signifi-
cantly correlated either with titres to PfCSP or to sporo-
zoites. Six of the volunteers from Mampong had P.
falciparum parasitaemia on the day samples were col-
lected. There was no significant difference in antibody
titres in all ELISA assays between subjects with or with-
out parasitaemia (p = 0.41 Mann Whitney U test two-
tailed).
Definition and frequency of positive ELISA responses in
urban and rural volunteers
Method 1 The mean ELISA activities from all the urban
or rural volunteers were greater compared with the
mean + 3 SD of the OD of control sera for at least one
antigen (Table 1 and Additional File 2). Four erythrocy-
tic stage antigens (EXP1, MSP1, MSP3 and EBA175),
and two pre-erythrocytic antigens SSP2/TRAP and LSA-
1 were frequently positive. A major exception was CSP
where only 2/14 (14%) of urban and 11/21 (52%) of
rural volunteers had positive responses. Urban volun-
teers were positive with fewer numbers of antigens than
rural volunteers (4.9 and 5.9 antigens/volunteer respec-
tively) and this difference was significant (p = 0.026,
Mann-Whitney U test, 2 tailed).
Method 2 When the more stringent second method was
applied (Table 1 and Additional File 3), the numbers of
urban and rural volunteers positive with CSP, SSP2/
TRAP, EXP1 and EBA175 declined compared to the
outcomes using the first method. However, all volun-
teers were positive with at least one malaria protein.
The frequencies of positive assays with LSA1 and MSP3
remained similar, but slightly declined for MSP1 and
declined more greatly for EXP1 and SSP2/TRAP. The
greatest decline was with EBA175 and CSP; CSP was
only positive with rural volunteers. The numbers of
antigens recognized by urban and rural volunteers were
3.4 and 3.9 antigens/volunteer respectively and this dif-
ference was not significant (p = 0.5), in contrast to
using method 1. The different outcome likely relates to
the lower frequencies obtained with method 2 compared
with method 1 for urban and rural volunteers (p = 0.02,
p = 0.001 respectively), and this was largely attributable
Figure 1 IFA titers of sera from volunteers in Accra or
Mampong compared with naïve controls from the US.
Horizontal bars represent geomean titers and filled circles represent
individual titers.
Figure 2 ELISA titers of sera from volunteers in Accra or
Mampong compared with naïve controls from Denmark.
Horizontal bars represent geometric mean titers and filled circles
represent individual titers. P values are the differences in activity for
each antigen between urban and rural Ghana populations; the only
significant difference was for MSP3.
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EBA175.
Six volunteers had malaria parasitaemia at the time
the samples were taken but they appeared to recognize
the same numbers of proteins as non-infected volun-
teers using method 1 and method 2 (Additional Files 2
and 3).
Ex vivo IFN-g ELISpot responses
Part A
Peptides used in Part A Six mixtures and three single
peptides (nine stimulants) of long DR-restricted and six
mixtures and 12 single peptides of HLA A or B-
restricted short peptides (18 stimulants) were used, and
were numbered 1-27 (see Additional File 4 for
sequences). Since this assay was based on matching the
HLA of each volunteer with matched HLA A- or B- or
DR peptides, not every volunteer was tested with every
peptide. The combinations that were tested are shown
in Additional File 5.
DR peptides: All volunteers were tested with five of
the DR-binding peptides (all of these being mixtures)
except one volunteer (v1340) who was not tested with
LSA3. The remaining four DR stimulants (one mixture
and three single peptides) were matched to varying
numbers of volunteers based on predicted HLA A or B
epitopes within their sequences. This resulted in 169
assays, 76 assays with 13 urban volunteers and 93 assays
with 17 rural volunteers (Table 2, Additional File 5)
HLA-A and B-restricted peptides: HLA matching pep-
tides were available for 15 volunteers for CSP, 13 volun-
teers for SSP2/TRAP and LSA1, and 12 volunteers for
EXP1 and LSA3, representing 17 of the 30 volunteers.
These included matches for HLA-A01, -A02, -A02.1,
-A03, -B07, -B35 and -B53. HLA matching for the A
and B loci was based on HLA type, not supertype. This
study did not have peptides matching the other HLA
alleles identified in the study subjects. This resulted in
96 assays; 52 assays with 8 urban volunteers and 44
assays with 9 rural volunteers (Table 2, Additional File
5).
Frequency of positive assays When all assays were ana-
lysed (Table 2), long DR-specific peptides elicited fewer
responses in urban volunteers (11/76 assays, 14.5%) than
rural volunteers (22/93 assays, 23.7%). Positive responses
to DR-specific peptides were approximately twice as fre-
quent as responses to short HLA class I peptides in
both populations (urban 3/52 assays 5.8%, rural 5/44
assays 11.4%,) (Table 2). In total, there were 14/128
(10.9%) positive assays with urban volunteers and 27/
137 (19.7%) positive assays with rural volunteers, sug-
gesting that ELISpot responses to individual peptides or
peptide pools were more frequent in rural than urban
volunteers, with the caveat that a restricted number of
Table 1 The frequency of positive ELISA activities conducted in urban and rural volunteers with 7 recombinant
proteins representing some candidate vaccine antigens
Method Antigens tested
1 Site No. vol CSP TRAP EXP1 LSA1 MSP1 MSP3 EBA Total Tot/v
Urban 14 2* (14%) 10 (71%) 11 (79%) 12 (86%) 11 (79%) 14 (100%) 8 (57%) 69 4.9
Rural 21 11 (52%) 21 (100%) 19 (90%) 20 (95%) 17 (81%) 20 (95%) 16 (90%) 124 5.9
Total 35 13 (37%) 31 (89%) 30 (86%) 32 (91%) 28 (80%) 34 (97%) 24 (86%) 192 5.5
2 Urban 14 0 (0%) 4 (29%) 5 (36%) 12 (86%) 10 (71%) 14 (100%) 2 (14%) 47 3.4
Rural 21 5 (24%) 10 (48%) 10 (48%) 19 (90%) 14 (67%) 19 (90%) 5 (24%) 82 3.9
Total 35 5 (14%) 14 (40%) 15 (43%) 31 (89%) 24 (69%) 33 (94%) 7 (20%) 129 3.7
Positive ELISA activities were defined using method 1 (OD that was above the mean of control negative donors (Danish volunteers with no previous exposure to
malaria) + 3 SD) or method 2 (OD ≥ 0.5 at a dilution of >1/100 and greater activity than control sera + 3 SD). The Table shows the numbers of urban and rural
volunteers that were positive with each antigen. The total numbers of antigens positive with urban and rural volunteers, and the frequency of positive antigens/
volunteer (Tot/v) are shown in the two right columns. * Number of volunteers positive.
Table 2 Frequency of positive ELISpot assays conducted in urban and rural populations using long (LP) and short (SP)
peptides
No. assays Total No. positive assays/all assays Total
Pop. LP SP LP+SP LP SP LP+SP
Urban (n = 13) 76 52 128 11/76 (14.5%) 3/52 (5.8%) 14/128 (10.9%)
Rural (n = 17) 93 44 137 22/93 (23.7%) 5/44 (11.4%) 27/137 (19.7%)
Total 169 96 265 33/169 (19.5%) 8/96 (8.3%) 41/265 (15.5%)
Six mixtures and 3 single peptides (9 stimulants) of long (DR-binding) or 6 mixtures and 12 single of short (HLA A or B-restricted) peptides (18 stimulants) were
tested with HLA-matched urban and rural volunteers. The number of assays that were performed and the number of assays that were positive are shown and
expressed as per cent of total assays. The sequences of the peptides, and how they were combined, are shown in Additional File 4.
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tions are shown in Additional File 5.
Frequency of positive volunteers Table 3 shows the
numbers of urban and rural volunteers responding to at
least one long or one short peptide. While urban volun-
t e e r sh a das l i g h t l yl o w e rf r e q u e n c yo fp o s i t i v er e s p o n -
ders than rural volunteers to long peptides (urban: 6/13
volunteers, 46.2%; rural: 9/17 volunteers, 52.9%) and to
short peptides (2/8 urban volunteers, 25%; 3/9 rural
volunteers, 33.3%), taken together, urban and rural
responders to both long and short peptides were similar
(urban 8/13 volunteers, 61.5% of volunteers; rural 9/17
volunteers, 52.9% of volunteers). Therefore, while rural
volunteers recognized more peptides than urban volun-
teers (Table 2), there was no difference in the frequency
of volunteers who were positive to one or more peptides
(Table 3).
Magnitude of ELISpot responses to long DR-restricted
peptides from each antigen The volunteers recognized
the 6 mixtures of DR-restricted long peptides but none
of the single peptides (Table 4). One mixture (number
22) and the 3 single peptides were only tested with 8
and 6 HLA A and B matched volunteers respectively,
and it is possible that testing more volunteers with these
peptides may have revealed additional positive out-
comes. Positive responses were obtained with peptides
from all five malaria protein st e s t e d :C S P ,S S P 2 / T R A P ,
LSA1, LSA3 and EXP1. ELISpot responses ranged from
70 - 430 sfc/m, and were similar for urban and rural
volunteers (p = 0.44 Mann Whitney U test two-tailed).
LSA1 was most frequently recognized (11/30 volunteers,
37%), followed by SSP2/TRAP (8 volunteers, 27%),
EXP1 (6 volunteers, 20%), LSA3 (4 volunteers, 14%) and
CSP (3 volunteers, 10%).
Magnitude of ELISpot responses to short HLA A- and
B-restricted peptides from each antigen O n l yaf e w
positive responses to short HLA A- and B-restricted
peptides were identified (Table 5) and this may reflect
the more limited numbers of volunteers and HLA-
matched peptides that were tested. 2/8 (25%) urban
volunteers (both HLA-A 02) recognized three short
Class I-restricted peptide mixtures from CSP, SSP2/
TRAP and LSA3. Three of nine (33%) rural volunteers
( H L AA 0 3a n dH L AB 5 3 )r e c o g n i z e df i v es h o r tC l a s s - I
restricted peptides (all single peptides) from CSP, SSP2/
TRAP, LSA1 and LSA3 (Table 5). Activities with short
peptides ranged from 73 to 258 sfc/m. Responses of
urban and rural volunteers to short peptides were simi-
lar (p = 0.65 Mann Whitney U test two-tailed).
Responses of urban and rural volunteers to short and
long peptides were also similar in both groups of volun-
teers (p = 0.58 and p = 0.39 for urban and rural, respec-
tively, Mann Whitney U test two-tailed). The sequences
of all positive long and short peptides are shown in
Additional File 4. In total, 14/32 (43.8%) short peptides
and 22/25 (88%) long peptides were active in these ELI-
S p o ta s s a y s ,e i t h e ra ss i n g l ep e p t i d e so ra sp a r to fm i x -
tures of peptides (Additional Files 4 and 5).
Effect of parasitaemia on ELISpot activity Six indivi-
duals in the rural population had malaria parasites when
venous blood samples were drawn, and three (50%)
were positive with long DR peptides (Table 4), but none
Table 3 Frequency of volunteers with positive ELISpot
responses conducted in 30 volunteers from urban and
rural populations
No. positive volunteers
Pop. No. LP positive No. SP positive Pos. All peptides
Urban (n = 13) 6/13 (46.2%) 2/8 (25.0%) 8/13 (61.5%)
Rural (n = 17) 9/17 (52.9%) 3/9 (33.3%) 9/17 (52.9%)
The numbers of urban or rural volunteers tested and the numbers positive for
at least one assay with long or short peptides is shown for each group. While
all volunteers were tested with at least one long DR peptide, only 8 urban
and 9 rural volunteers were tested with short HLA A or B-matched peptides.
Table 4 Individual urban and rural volunteers’ fresh
ELISpot activity with DR-matched long Class II-restricted
peptides
CSP SSP2 LSA1 LSA3 EXP1
Site Vol. D44,
D49
D46,
D47
D51-
D59
D64-
D68
D70,
D72
D60,
D61
Urban 113 295 145 283 233 208
614 103
815 110
816 83
917 250 70
1123
+
365
Rural 1324 90 88 245
1326 85 140 100 98 113
1330
+
200 103
1331 150 193 318
1332 243 343
1341 83 100 210 168
1342 430
1345 95
1351
+
70
All 30 volunteers were tested with DR peptides from CSP (four), SSP2/TRAP
(nine), EXP1 (two), LSA1 (five) and LSA3 (two), except for volunteer 1340, who
was not tested against LSA3. Six of 13 urban and nine of 17 rural volunteers
had ELISpot activities that were identified as positive and are listed in this
table. Each number represents the mean of quadruplicate wells in a single
assay expressed as sfc/m, with medium controls subtracted. A “+” next to the
volunteer identification number in the second column indicates patent
parasitemia at the time the sample was taken [see Methods]. The peptides
that were not recognized by any of the volunteers as well as the volunteers
not having any positive responses are shown in Additional File 5.
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frequency of ELISpot responses to class I peptides may
be influenced by circulating parasites.
Comparison of ELISA and ELISpot activities When
ELISA (Additional Files 2 and 3) using method 1 and
ELISpot data (Tables 4 and 5) were examined, almost all
urban and rural volunteers with positive ELISpot activ-
ities were also positive with the same antigen in ELISA,
except v506 and v816 who were negative in ELISA and
positive in ELISpot (with CSP D4, D5; D64-68 respec-
tively). This may only reflect the high frequency of posi-
tive volunteers identified using method 1. However,
w h e nt h em o r es t r i n g e n tm e t h od 2 analysis of positive
ELISA activities was used (Additional File 3) the lower
numbers of positive assays with CSP, SSP2 and EBA175
reduced this concordance, although 10/11 positive ELI-
Spot assays with LSA-1 remained positive in ELISA.
Part B
Volunteers and sample schedules The objective of Part
B was to collect PBMC at two time points and to
perform ELISpot assays of cells from each of the two
time points on three separate days. Twelve volunteers
were initially enrolled, but only seven volunteers were
u s e df o rt h i sa n a l y s i sa st h e s es e v e nc o m p l e t e db l o o d
draws when scheduled and sufficient blood was obtained
to conduct nearly all the planned assays for one or both
antigens. There were five with complete samples for
both antigens, one with complete samples for CSP only
(totalling six for CSP) and one with complete samples
for AMA1 only (totalling six for AMA1). The sample
availability is shown in Table 6.
PBMC were collected at days 0, 9, 14 and 21 and fro-
zen. Assays were performed on frozen samples after all
samples had been collected. Samples from day 0 and
day 14 were tested in ELISpot assays with CSP peptide
pools, and samples from days 9 and 21 were tested with
AMA1 peptide pools. Three assays, labeled assays 1, 2
and 3, were performed on three separate days for each
time-point, starting in each case with freshly thawed
PBMCs. Thus with six volunteers for CSP (v1024,
v1036, v1039, v1041, v1054 and v1056), 36 assays per-
formed with 9 CSP peptide pools for a total of 324 indi-
vidual assays; and with six volunteers for AMA1 (v1024,
v1036, v1039, v1054, v1056 and v1001), 35 assays were
performed with 12 peptide pools (v1036 was only tested
in two assays at the day 9 time point due to shortage of
PBMC) for a total of 420 individual assays. In addition
there were 71 medium controls assayed for the seven
volunteers.
Variability in medium controls The first step was to
determine the variation in ELISpot responses in control
assays when PBMC’s were stimulated with medium
alone to establish a baseline against which positive ELI-
Spot activities could be statistically calculated. The
values of the medium only controls were examined for
each of the 12 volunteers, for CSP and for AMA1, at
the two time-points each with three assays (100 control
Table 5 Individual urban and rural volunteers’ ELISpot
activity with HLA A or HLA B-matched short Class I-
restricted peptides
CSP SSP2/TRAP LSA1 LSA3
Site Vol. D4, D5 D6 D12-D14 D15 D29 D31-D35 D37
Urban 506 173 NT 180
510 73 NT
Rural 1326 95 88 NT NT
1331 93
1341 NT NT NT NT 258 208
HLA-matches were defined for an HLA A or B allele. Two of 13 urban (506 and
510) and three of 17 rural (1326, 1331 and 1341) volunteers had positive
ELISpot responses with HLA-matched short Class I-restricted peptides. Each
number represents the mean of quadruplicate wells in a single assay with
medium subtracted. No volunteer was infected with malaria. None of the
twelve volunteers tested with EXP1 peptides were positive. NT = Not Tested:
Table 6 Part B assay schedule
CSP SAMPLE 1 AMA SAMPLE 1 CSP SAMPLE 2 AMA SAMPLE 2
Day 0 0 0 9 9 9 14 14 14 21 21 21
Assay 1 2 3 1 2 3 1 2 3 1 2 3 TOTAL
1001 X X X X X X 6
1024 X X X X X X X X X X X X 12
1036 X X X X X X X X X X X 11
1039 X X X X X X X X X X X X 12
1041 X X X X X X 6
1054 X X X X X X X X X X X X 12
1056 X X X X X X X X X X X X 12
TOTAL 6 6 6 6 5 6 6 6 6 6 6 6 71
Each volunteer was sampled at different time points (for CSP day 0 and day 14; AMA1 day 9 and day 21). Frozen PBMC from each time point were tested in
ELISpot assays with CSP or AMA peptide pools in three assays 1, 2 and 3 on different days as indicated. Assays used for analysis are boxed. X indicates where
that volunteer was tested with CSP or AMA1 pools. The seven volunteers in the table were analysed for ELISpot reproducibility at each of the two time points
(Supplementary Tables 1, 2 and 3). Totals refer to the numbers of assays used in this analysis. An additional five volunteers enrolled in the study and tested at
some time points were excluded from this table and from the consistency analysis because data sets were not sufficiently complete.
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sampled at each time point). The frequency distribution
of the medium controls is shown in Figure 3. When
examined by antigen, they were nearly identical (Figure
3), with most values between 0-15 sfc/m. This indicated
a high degree of similarity regarding how the assays per-
formed on different days, and therefore that assay
results for different antigens or from different days
could appropriately be compared.
Reproducibility of assays
When ELISpot activities of all peptide pools were ana-
lysed, 138/324 (42.6%) of CSP assays and 236/420
(56.2%) of AMA1 assays were greater than medium con-
trols (Table 7). The remaining peptide-pool activities
were similar to medium controls, and could be consid-
ered as natural variability or “noise” of the ELISpot
assay. The next step was to differentiate which activities
were significantly different from medium controls and
three sets of criteria were applied (See Methods).
Method 1
The simplest and least stringent method was to subtract
the average of medium control activity from the average
of antigen-stimulated activity and use a net difference of
20 sfc/m as the arbitrary cut-off [50]. The results are
summarized in Table 7 and Figure 4 and details are pro-
vided in Additional File 6.
Positive volunteers
Thirty/324 (9.3%) assays with CSP and 94/420 (22.4%)
assays with AMA1 pools were positive at this cut off
(Table 7, details in Additional File 6). When all CSP
positives were combined, v1054 was consistently positive
(positive in all three assays) at both time-points, and
v1039 and v1041 were consistently positive only at a
single time point (Figure 5, details in Additional File 6).
When positive responses to AMA1 were combined,
v1039, v1054 and v1056 were consistently positive (posi-
tive in all three assays) at both time points, and v1001
and v1024 were consistently positive at one time point.
v1036 was positive in both available samples at the first
time-point. The remaining assays were positive at one
or two of three assays at a given time-point.
Negative volunteers
With CSP v1036 was consistently negative (0/3 assays)
at both time-points and 1024 and v1056 were consis-
tently negative at single time-points. None were consis-
tently negative with AMA1.
Positive peptide pools
When responses to individual peptide pools were exam-
ined (Table 7, details in Additional File 6), Cp1 was the
most frequently positive CSP peptide pool (16/30, 53%)
whereas other CSP peptide pools were less frequently
positive. For AMA1, five volunteers (v1024, v1036,
v1039, v1054 and v1056) recognized Ap7 and Ap9 in 40
of the total 84 positive assays (47.6%), and only one of
the 30 positive assays were not positive with Ap7 and
Ap9 combined. Activities to Ap7 and Ap9 (that do not
overlap) appeared to be linked (R
2 =0 . 6 3 ,C h i - s q u a r e ,
two-tailed p = 0.79) whereas no other peptide pools
were similarly linked (Figure 6). The 6
th volunteer
(v1001) primarily recognized Ap4 and Ap8 in 3/6 assays.
Method 2
The second method used Student’s t test, a ratio of test
wells to medium controls of greater than two, and a
greater than 10 sfc/m difference over medium control
and was also used in Part A.
Positive volunteers
This method identified 17/324 (5.2%) CSP and 62/420
(14.8%) AMA1 assays as positive (Table 7, details in
Additional File 7), and these frequencies were lower
than using Method 1. This method identified consistent
results with CSP (3/3 assays positive) with v1054 (both
time points) and with AMA1 with v1054 and v1056
(both time points positive) and v1039 (single time
points) and v1036 (2 positive assays of 2 available sam-
ples) (Figure 5, details in Additional File 7).
Negative volunteers
v1056 was consistently negative (0/3 assays) at both time
points with CSP, and v1024, v1036 and v1041 were con-
sistently negative at one time-point. However, no volun-
teers were consistently negative with AMA1.
Positive peptide pools
For CSP, only Cp1 and Cp9 induced positive activities,
and most were induced by Cp1 (13/17 and 76.5%,
respectively, Figure 5, details in Additional File 7). For
AMA1, Ap7 and Ap9 together induced most positive
Figure 3 The frequency distribution of the medium controls
(sfc/m PBMC) for all the CSP and AMA1 assays. The numbers of
medium controls from each assay are distributed against the
ELISpot activity (sfc/m). The distribution of medium controls from all
assays using CSP or AMA1 peptide pools, and the total using both
antigens, show the same distribution.
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60.0%, respectively), and other AMA1 peptide pools
were only positive when Ap7 and Ap9 were positive.
v1001 only recognized Ap4 and Ap8.
Method 3
This was the most stringent and used two criteria: 55
s f c / ma sam i n i m u mc u to f fa n da4 - f o l do rg r e a t e rd i f -
ference between test wells and medium controls.
Positive volunteers
This method identified 10/324 (3.1%) CSP and 41/420
(9.8%) AMA1 positive assays (Table 7, details in Addi-
tional File 5), and these were lower than using Methods
1 or 2. This method gave the lowest frequency of con-
sistent outcomes (all three sets at either time point).
v1054 was positive with CSP and AMA1 with all three
assays at both time points; v1039 and v1056 gave consis-
tent positives with AMA1 in all assays at one time
point, and v1036 was positive with both available sam-
ples at one time-point (Figure 5, details in Additional
File 5).
Negative volunteers
With CSP, v1024, v1036 and v1056 were consistently
negative (0/3 assays) at both time points, and v1039 and
v1041 were consistently negative at one time-point.
Only v1036 was consistently negative with AMA1 at
one time point.
Positive peptide pools
For CSP, Cp1 induced 9/10 positive activities (90%) and
Cp1 induced 1 positive activity. With AMA1 29/36
(80.1%) were positive with Ap7 and Ap9 combined,
excluding v1001 (Table 7, details in Additional File 5).
The numbers of positive assays with Ap7 and Ap9 were
least affected by increasing the stringency of the analyti-
cal method used.
Combined ELISpot responses to CSP and AMA1
CSP and AMA1 responses were added together (Figure
5) for those 5 volunteers who were tested with both
peptides (v1024, v1036, v1039, v1054 and v1056). Since
both samples of v1036 at one time-point were consis-
tently positive with AMA1 it was included within the 3/
3 positive group to give 10 time-points. The consistent
(3/3 and 0/3) and the inconsistent outcomes (2/3 and 1/
3) were combined (Figure 7). Method 1 gave the great-
est numbers of consistent (80%) and fewest numbers of
inconsistent (20%) outcomes compared to Methods 2
and 3 (60% and 40% consistent, respectively).
Comparison of the Two Time Points
There was only modest consistency when two time
points approximately two weeks apart were compared.
Each time point was classified as positive (3/3 assays
positive), negative (0/3 assays positive) or indeterminate
(2/3 or 1/3 assays positive), then the number of positive,
negative or indeterminate results that were concordant
between the two time points were calculated. For
Method 1 the number of consistent assays that were
positive, negative or indeterminate were 4, 1 and 0,
respectively or 5/12 overall (both antigens); for Method
2: the numbers were 3, 1 and 2, respectively, or 6/12
overall; and for Method 3: the numbers were 2, 3 and 2,
respectively, or 7/12 overall. Thus, overall, in only about
half the cases were the results at one time-point repro-
duced at the second time point two weeks later.
Discussion
Malaria vaccine development is focused on a variety of
candidate antigens including those in this study. In par-
ticular, prime-boost strategies designed to elicit
Table 7 Summary of assays with positive ELISpot activities using statistical Methods 1, 2 and 3
CSP AMA1
Method Assays No. Positive Cp1* Assays No. Positive Ap7and9**
>Med. 324 138 (42.6%) 30/138 (21.7%) 420 236 (56.2%) 53/201 (26.3%)
1 324 30 (9.3%) 16/30 (53.0%) 420 94 (22.4%) 40/84 (47.6%)
2 324 17 (5.2%) 13/17 (76.5%) 420 62 (14.8%) 34/57 (60.0%)
3 324 10 (3.1%) 9/10 (90%) 420 41 (9.8%) 29/36 (80.1%)
ELISpot activities >medium controls were analysed using Methods 1, 2 and 3 (see Methods) and the positive activities for each method are shown. The numbers
of Cp1 are for all volunteers tested, Ap7+Ap9 excluding v1001 who responded to different peptide pools. * Proportion of positive assays that are positive by Cp1;
** Proportion of positive assays that are positive by Ap7 or Ap9 excluding v1001.
Figure 4 Method 1: mean ELISpot activity of all positive assays
of peptide pool stimulated PBMC compared with medium-only
controls. ELISpot activities of each set of individual volunteers are
plotted against their corresponding medium only controls. Each
symbol represents the mean of the triplicates and the black dotted
line represents >55 sfc/m activity.
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Figure 5 Positive ELISpot activities with CSP or AMA1 peptide pools with Methods 1, 2 or 3. The top three rows for each volunteer
denote the three replicate assays for the first time point, and the second three rows denote the three replicate assays for the second time-
point. An assay is considered positive if at least one peptide pool was positive using that method. All positive CSP and AMA1 activities are
shown in light or medium gray respectively. The responses of the five volunteers (v1024, v1036, v1039, v1054 and v1056, for whom both CSP
and AMA1 assays were performed) were combined and shown in dark gray. *Assay not done.
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with protection are moving to immunogenicity and effi-
cacy studies in endemic populations. A long-term goal
of these studies is to establish antibody and T cell assays
at sites in Southern Ghana that might be used for clini-
cal trials[51,52]. To achieve this there were two aims.
Firstly (Part A) to establish the ELISA, IFA and ELISpot
assays at this study site, and secondly (Part B) to
develop the ELISpot assay best suited to test potential
vaccine cohorts especially where naturally-acquired
activities are low and without requiring HLA typing of
the volunteers. ELISpot assays have been used widely in
measuring vaccine-induced T cell activities in non-ende-
mic populations where background (pre-immunization)
activities are usually low compared to those in malaria-
endemic populations, and there is little information con-
cerning the reproducibility of ELISpot assays in endemic
populations.
Antibody assays
Using a panel of recombinant proteins representing
seven candidate vaccine antigens, ELISA detected rela-
tively low antibody responses that trended higher in
rural Mampong-Akwapim than urban Accra, a differ-
ence that was statistically significant only for MSP3, sug-
gesting that the higher malaria prevalence in the rural
population had only a marginal association with
increased antibody responses to most antigens. IFA
assays detected anti-sporozoite and anti-red blood cell
antibodies with roughly equal frequency in volunteers
from the two study sites, and IFA titres correlated with
ELISA activities. Most adults possessed demonstrable
anti-malaria antibodies as would be expected in an
endemic adult population (see for example[30,53,54]
where malaria transmission occurs throughout the year).
When two criteria of lower and higher stringency were
used to classify ELISA responses as positive or negative,
all volunteers were positive to at least one antigen using
either method. However, positive responses to the pre-
erythrocytic antigen CSP, but not SSP2/TRAP, were rare
in urban volunteers compared to rural volunteers, per-
haps indicating that rural volunteers were being bitten
more frequently by infected mosquitoes. The numbers
of positive antigens decreased when stringency increased
particularly with CSP. This analysis may suggest that the
lower stringency analysis was more useful to distinguish
rural and urban communities with regard to pre-
Figure 6 Method 1: Linkage of ELISpot activities. Left panel:E L I S p o ta c t i v i t i e so fA p 7a n dA p 9s h o wm o d e r a t el i n k a g e( r
2 = 0,63). Right
panel: no linkage between Ap7 and Cp1 (r
2 = 0.03).
Figure 7 Comparison of positive assays using Methods 1, 2
and 3. The number of time-points with assays that were all positive
(3/3), all negative (0/3) or 1/3 or 2/3 positive using Methods 1, 2 or
3 are expressed as percent of total number. For CSP and AMA1, the
numbers of time-points that were 3/3 positive was highest using
Method 1 and dropped with Method 2 and was lowest with
Method 3. Conversely, the number of time-points that were all 3/3
negative was lowest with Method 1 and rose with Method 2 and
was highest with Method 3. When CSP and AMA1 were combined,
Method 1 identified more 3/3 positive or 3/3 negative (0/3 positive)
time-points than Methods 2 or 3.
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observation that positive ELISA activities to these anti-
gens using the lower stringency analysis were more con-
cordant with ELISpot activities (see below). The
importance of defining antibody titers in naturally-
acquired immunity has been underscored by recent
longitudinal studies that established correlations
between higher IgG levels to several antigens tested in
this study and reduced risk of clinical malaria in North-
ern Ghana[55,56], Kenya[57] and Burkina Faso[53].
ELISpot assays (using HLA-matched peptides)
Since T cell responses to malaria antigens are often
HLA-restricted[36,37], it seemed likely that the greatest
sensitivity of the ELISpot assay would be achieved using
HLA-matched peptides with appropriate length for sti-
mulating Class I or Class II responses. To define back-
ground ELISpot responses to five candidate malaria
vaccine antigens, Method 2 was used to identify positive
outcomes. The criteria required a statistically significant
difference between replicate test (peptide stimulated)
wells and medium-only control wells (Students t test)
and at least a two-fold, 10 sfc/million difference.
The numbers of urban and rural volunteers who were
positive with long DR or short HLA A or B peptides was
similar, although rural volunteers recognized more anti-
gens than urban volunteers. However, CSP responses
were rare, with a higher frequency of responses to LSA1
or SSP2/TRAP, particularly to DR-restricted peptides, in
both urban and rural areas. This may reflect different
transmission patterns in these two sites as increased
transmission in the rural site may induce higher fre-
quency of CSP responses. The average of all positive
responses was >70 sfc/m, and some responses were as
high as 430 sfc/m. An earlier study showed that ELISpot
responses to non-HLA-matched CSP peptides in The
Gambia were very low, 23 + 11 sfc/m[58], suggesting that
HLA-matched peptides and volunteers may be a more
sensitive assay of ELISpot responses than using individual
non-matched peptides. As in other studies[25], malaria
infection appeared to suppress ELISpot responses to
short peptides, suggesting that the frequency of volun-
teers, particularly in rural areas, with class I-restricted
ELISpot responses may be underestimated.
One of the challenges associated with using this
approach is determining the appropriate peptides to test.
We selected peptides based on the HLA of the volunteers
and the availability of HLA-matched peptides. DR-binding
epitopes are relatively promiscuous and bind to more than
one DR haplotype [59-62], and all volunteers were tested
against 5 DR peptides regardless of HLA type, although an
additional 4 DR peptides were matched to a subset of
volunteers based on HLA A or B epitopes contained
within them. Utilizing the peptides available, only about
half of the volunteers could be tested with HLA A and B
matched short peptides; thus it is difficult to know if
response rates might have been significantly higher had
more epitopes been synthesized and tested. In addition,
matching was performed on the basis of HLA type without
taking into account supertype, which could have allowed a
larger number of peptides to be matched to each volun-
teer. Overall, this approach was cumbersome and led to a
complex experimental design (Additional Files 7 &8) that
likely contributed to underestimating the frequency of
positive responses.
Analysis of reproducibility (using overlapping peptides)
The second aim was to determine the reproducibility of
the ELISpot assay. Due to the challenges associated with
using HLA-matched peptides, an alternative approach
was adopted for Part B - to test all volunteers against
uniform pools of overlapping peptides without HLA
testing, on the assumption that such peptides would
contain all T cell epitopes that could be recognized by
the volunteers and that the uniform, 15 amino acid
length would elicit Class I or Class II responses. The
apparent dependence of CD8+ T cell responses to plas-
modial antigens on CD4+ T cells ([37,63-65] may reflect
that CD4+ and CD8+ T epitopes often overlap.
Usually ELISpot assays are performed once, using
replicate wells. However, it is uncertain whether a single
assay accurately represents T cell activities, especially in
an area where they are low. To address this, two blood
samples were drawn from each volunteer approximately
two weeks apart, PBMC were frozen and then tested in
three assays on different days. If the ELISpot assay is
reproducible then all three assays at a single time point
should be either all positive or all negative.
Ex vivo ELISpot assays - analysis of reproducibility
Of critical importance in determining ELISpot reprodu-
cibility are the criteria used to identify which of the rela-
tively low, infrequent and unstable ELISpot responses
induced by malaria transmission[7-9,28] should be con-
sidered positive. Unlike vaccine trials, where post-immu-
nization responses are differentiated by comparison with
pre-immunization samples, naturally-acquired responses
can only be differentiated by comparison with medium-
only controls. Analysis of ELISpot responses using pep-
tide pools was complex as about half of all responses
were within the range of medium-only controls. In that
case, the choice of statistical analysis to determine posi-
tive activities was crucial. Such analyses identify a cut
off value above which an activity is considered positive.
If the cut off is low more activities are likely to be deter-
m i n e dt ob ep o s i t i v et h a nu s i n gah i g hc u to f f .T o
explore this effect, three statistical methods of increasing
stringency were applied. The least stringent method
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trol and test sample) gave the greatest number of con-
sistently positive (3/3) assays and the fewest where 1/3
or 2/3 were positive (Figure 7). More stringent analyses
such as the Student’s t test that has been used in vac-
cine trials[48] and was used in Part A, or a defined ELI-
Spot activity that was four times and at least 55 sfc/
million greater than the median of medium only con-
trols[35], identified fewer positive assays and fewer
instances when three replicate assays were consistently
positive. Overall, the least stringent method yielded 80%
consistent results while the other two yielded 60% con-
sistent results, indicating that at least in this population,
a simple assessment relying on a 20 sfc/million differ-
ence may be most suitable.
More volunteers were positive with AMA1 than CSP,
consistent with previous studies that T cell immunity to
blood stage antigens was detected in 67% of individuals
[8] and less frequently with pre-erythrocytic antigens
[9,28]. Although not an objective of this study, this high
f r e q u e n c yo fTc e l lr e s p o n s e st oA M A 1m a yb ea s s o -
ciated with the effect of naturally acquired immunity on
reducing severe disease[66].
Three peptide pools appeared to detect responses in
most volunteers; Cp1, Ap7 and Ap9. Cp1 is known to con-
tain HLA-A02, HLA-A24 and HLA-B44 T cell epitopes
[36,64], Ap7 and Ap9 also contain previously identified
proliferative epitopes[24], and Ap7 also contains a CD8+
T cell restricted epitope[31]. The Cp1 responses were con-
sistent with those elicited by the mixture of HLA-A02-
restricted D4 and D5 as D4 is contained within the pep-
tides in Cp1. In Part A using HLA-matched peptides a
total of 2/13 urban volunteers showed positive responses,
whereas 3/6 volunteers in Part B showed positive
responses with CSP peptide pools. Although ELISpot
activities of both Part A and B with peptides or peptide
pools were similar (fresh cells were used in Part A and fro-
zen cells in Part B), peptide pools may elicit positive
responses in more volunteers than HLA-matched pep-
tides. This is not surprising as Cp1 contains at least 3
known HLA-restricted epitopes and may thus be better
able to detect responses in a wider population than using
a few HLA-matched peptide epitopes. Responses to Ap7
and Ap9 appeared to be linked and both pools appeared
to contain immunodominant epitopes,
It remains to be demonstrated whether vaccines
induce the same dominant responses in volunteers in
malaria-endemic areas as have been induced in those
volunteers through natural transmission. Thus, in any
potential vaccine trials in Ghana, ELISpot assays may
have to be further refined to distinguish vaccine-induced
T cell immunity from that naturally acquired.
ELISpot responses varied significantly over even short
periods of time. When the proportion of consistently
positive and consistently negative assays were compared
between the two time points, which were separated by
j u s tt w ow e e k s ,o n l yi na b o u th a l ft h ec a s e sw e r et h e
outcomes the same. This is consistent with the findings
in other studies that T cell responses are relatively
unstable over time[8,28,50]. It is not possible to quantify
the degree to which these differences may have been
affected by assay variation.
Recently, some of the most powerful studies have used
protein arrays to measure the responses to many anti-
gens simultaneously, identifying antigen clusters for
which immunological recognition may imply clinical
resistance to malaria[67,68] and this approach may be
highly applicable to further studies at the sites in Ghana.
The interpretation of array data faces the same ques-
tions regarding criteria for positivity as addressed in the
current study.
Conclusions
This study demonstrated that antibody assays, ELISA and
IFA, could successfully measure antibodies in Ghana to
malaria antigens undergoing vaccine development. Like-
wise, the ex vivo ELISpot assay was shown to reproduci-
bly measure T cell IFN-g activities despite responses
being low and variable, but reproducibility depended
partly on the statistical method used to determine posi-
tive activities. Due to ease of use, overlapping peptides
appeared to be preferable to HLA typing and the use of
HLA-matched peptides. For ELISA, the more stringent
criteria for positivity may have better distinguished rural
and urban populations, at least for pre-erythrocytic stage
antigens. For ELISpot, the least stringent method tended
to yield the most consistently reproducible outcomes. For
both humoral and cellular assays, further work is needed
to demonstrate the generalizability of these findings. Bet-
ter understanding of how to conduct these assays in
endemic areas is important given the requirement for
their use in malaria vaccine studies at these sites.
Additional material
Additional File 1: Part A: Volunteers tested in IFA, ELISA and
ELISpot Assay. Thirty five volunteers met selection criteria and were
used in antibody (IFA and ELISA) assays. Thirty of these volunteers were
HLA-typed and used in ELISpot assays.
Additional File 2: Positive ELISA activities defined using Method 1.
Positive ELISA activities were defined as the mean Ghanaian volunteer
OD ≥ mean control sera + 3 SD. Shaded cells show positive assays with
each antigen. The numbers of positive assays per volunteer, the total
number of positive assays for urban and rural populations and the mean
number of positive assays/volunteer for each population are shown in
the two right columns. The total numbers of urban and rural volunteers
positive with each protein are shown in the bottom rows. A “+” next to
the volunteer identification number in the second column indicates
patent parasitemia at the time the sample was taken [see Methods].
Volunteers tested in ELISpot assays using DR-binding or HLA A and B-
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Page 15 of 18matched peptides shown by X and @ (Tables 3 and 4), and these
indicate positive assays with each volunteer.
Additional File 3: Positive ELISA activities defined using Method 2.
Positive ELISA activities were defined as the mean Ghanaian volunteer
OD ≥ mean control sera + 3 SD and at minimum titer of 100. Shaded
cells show positive assays with each antigen. The numbers of positive
assays per volunteer, the total number of positive assays for urban and
rural populations and the mean number of positive assays/volunteer for
each population are shown in the two right columns. The total numbers
of urban and rural volunteers positive with each protein are shown in
the bottom rows. A “+” next to the volunteer identification number in
the second column indicates patent parasitemia at the time the sample
was taken [see Methods]. Volunteers tested in ELISpot assays using DR-
binding or HLA A and B-matched peptides shown by X and @ (Tables 3
and 4), and these indicate positive assays with each volunteer.
Additional File 4: Part A: Sequences of all short and long peptides
tested in ELISpot assays. Peptides were either used alone or in
mixtures as indicated by horizontal divisions in the second and last
columns. Each was assigned a number (last column) that was used to
identify which was tested with each volunteer (Additional Table 5).
Shaded cell indicate peptides or peptide mixture that elicited positive
ELISpot activities in at least one volunteer. *Peptides D44 and D49 were
used together.
Additional File 5: Urban and rural volunteers: HLA-A and HLA-B
supertypes and HLA matched peptides. Volunteers had low to
medium resolution HLA typing (see Methods) and tested with HLA-
matched peptides (gray cells). DR of each volunteer is not shown.
Positive assays are shown in black cells. *Uncertain assignment. NA Not
available. To identify the peptides for each column, refer to Additional
Table 4 using the reference number provided in the second row (1-27).
Additional File 6: ELISpot activities to CSP or AMA1 peptide pools
in replicate assays using Method 1. ELISpot activities were determined
by subtracting the medium controls from the test peptide pool, and
used an arbitrary cut off of a net value of 20 sfc/m. Positive outcomes
for each set are shown in light gray (CSP) and medium gray (AMA1);
individual activities were combined to give a total CSP (C, light gray) or
AMA1 (A, medium gray) response. V = volunteer ID; T = time-point; A =
assay number. The first three rows for each volunteer are the three
assays for the first time-point, while the second three rows are the assays
for the second time point. Missing samples are indicated by dots.
Additional File 7: ELISpot activities to CSP or AMA1 peptide pools
in replicate assays using Method 2. ELISpot activities were determined
using the Student’s t test to analyze specific differences (p = <0.05, two
tailed) between test peptide pool and medium controls, and were
considered positive if the test activity was at least twice that of the
medium controls and the difference was at least 10 sfc/m. Positive
outcomes for each set are shown in gray; individual activities were
combined to give a total CSP (C, light gray) or AMA1 (A, medium gray)
response. V = volunteer ID; T = time-point; A = assay number. The first
three rows for each volunteer are the three assays for the first time-
point, while the second three rows are the assays for the second time
point. Missing samples are indicated by dots.
Additional File 8: ELISpot activities to CSP or AMA1 peptide pools
in replicate assays using Method 3. ELISpot activities were positive if
the median of peptide pools was >55 sfc/m and at least four times the
median of the medium controls. Positive outcomes for each set are
shown in gray; individual activities were combined to give a total CSP (C,
light gray) or AMA1 (A, medium gray) response. V = volunteer ID; T =
time-point; A = assay number. The first three rows for each volunteer are
the three assays for the first time-point, while the second three rows are
the assays for the second time point. Missing samples are indicated by
dots.
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